179
Participants
Start Date
July 31, 2011
Primary Completion Date
April 18, 2019
Study Completion Date
April 18, 2019
MGA271
"Up to 9 dose escalation cohorts will be enrolled to determine the maximum tolerated dose of MGA271. Patients with evidence of clinical benefit will be allowed to continue therapy at the same dose once per week for 3 weeks out of every 4-week cycle until documented progression.~Patients treated in the Expansion Segment at the maximum administered dose will receive weekly, uninterrupted infusions of MGA271 in 8 week cycles for up to 12 cycles."
Hospital of the University of Pennsylvania/Abramson Cancer Center, Philadelphia
University of Maryland, Baltimore
Carolina Biooncology Institute, Huntersville
Moffitt Cancer Center, Tampa
Sarah Cannon Research Institute, Nashville
Norton Cancer Institute, Louisville
The University of Chicago, Chicago
UCLA Hematology-Oncology Clinic, Los Angeles
Yale Cancer Center, New Haven
Neely Center for Clinical Cancer Research, Tufts Medical Center, Boston
Massachusetts General Hospital Cancer Center, Boston
Dana Farber Cancer Institute, Boston
Lead Sponsor
MacroGenics
INDUSTRY